Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan-Feb;87(1):135-143.
doi: 10.25259/IJDVL_342_20.

What is new in dermatotherapy?

Anupam Das  1 , Anand Toshniwal  2 , Bhushan Madke  3
Affiliations
Free article
Review

What is new in dermatotherapy?

Anupam Das et al. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb.
Free article
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. De Luca G, Cariddi A, Campochiaro C, Vanni D, Boffini N, Tomelleri A, et al. Efficacy and safety of apremilast for Behçet's syndrome: A real-life single-centre Italian experience. Rheumatology (Oxford). 2020; 59:171-5 - DOI - PubMed
    1. Vossen AR, van Doorn MB, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol. 2019; 80:80-8 - DOI - PubMed
    1. Simpson EL, Imafuku S, Poulin Y, Ungar B, Zhou L, Malik K, et al. A phase 2 randomized trial of apremilast in patients with atopic dermatitis. J Invest Dermatol. 2019; 139:1063-72 - DOI - PubMed
    1. Vernero M, Ribaldone DG, Cariti C, Ribero S, Susca S, Astegiano M, et al. Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease. J Dermatol. 2020; 47: e216-e217 - DOI - PubMed
    1. Laird ME, Tong LX, Lo Sicco KI, Kim RH, Meehan SA, Franks AG, Jr. Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum. JAAD Case Rep. 2017; 3:228-9 - DOI - PubMed

LinkOut - more resources